Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Shares Outstanding (Diluted Average) (2022 - 2025)

Mangoceuticals' Shares Outstanding (Diluted Average) history spans 4 years, with the latest figure at $10.1 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 408.93% to $10.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.1 million, a 408.93% increase, with the full-year FY2025 number at $10.1 million, up 408.93% from a year prior.
  • Shares Outstanding (Diluted Average) hit $10.1 million in Q4 2025 for Mangoceuticals, down from $11.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for MGRX hit a ceiling of $14.5 million in Q2 2023 and a floor of $1.1 million in Q3 2023.
  • Historically, Shares Outstanding (Diluted Average) has averaged $6.1 million across 4 years, with a median of $4.6 million in 2025.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): crashed 90.05% in 2023 and later surged 472.25% in 2025.
  • Tracing MGRX's Shares Outstanding (Diluted Average) over 4 years: stood at $10.8 million in 2022, then crashed by 90.05% to $1.1 million in 2023, then soared by 84.23% to $2.0 million in 2024, then soared by 408.93% to $10.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for MGRX at $10.1 million in Q4 2025, $11.5 million in Q3 2025, and $7.3 million in Q2 2025.